200 related articles for article (PubMed ID: 1907433)
21. [An evaluation of two postoperative chemotherapy protocols in ovarian common epithelial cancer: a comparison of continuous and intermittent hospitalization].
Sakamoto H; Suzuki H; Hayakawa S; Kiseki Y; Miyakawa Y; Ohkubo Y; Watanabe Y; Takami M; Kashiwazaki K; Tanaka H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1491-4. PubMed ID: 2584826
[No Abstract] [Full Text] [Related]
22. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
Levin L; Hryniuk W
Semin Oncol; 1987 Dec; 14(4 Suppl 4):12-9. PubMed ID: 3120317
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy of ovarian cancer.
Ozols RF; Young RC
Semin Oncol; 1984 Sep; 11(3):251-63. PubMed ID: 6435250
[No Abstract] [Full Text] [Related]
24. [Use of metoclopramide and dexamethasone in preventing vomiting associated with antineoplastic chemotherapy].
Sobkowski W; Jassem J
Pol Tyg Lek; 1987 Jul 6-7; 42(27-28):841-3. PubMed ID: 3684761
[No Abstract] [Full Text] [Related]
25. [High-dose chemotherapy in ovarian adenocarcinoma].
Lotz JP; Lhommé C; Pautier P; Couteau C; Gligorov J; Alexandre J; Selle F; Izrael V; Maraninchi D; Viens P
Bull Cancer; 2000 Jan; 87(1):63-9. PubMed ID: 10673633
[No Abstract] [Full Text] [Related]
26. Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
Razis DV; Poulakou E; Petounis A; Papadimitriou G; Kosmides P; Delides G
Oncology; 1982; 39(4):205-8. PubMed ID: 6806735
[TBL] [Abstract][Full Text] [Related]
27. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
28. The sequential multiple modality treatment of ovarian cancer.
Dembo AJ
Radiother Oncol; 1985 Apr; 3(3):187-92. PubMed ID: 3923573
[No Abstract] [Full Text] [Related]
29. Radiotherapeutic management of ovarian cancer.
Dembo AJ
Semin Oncol; 1984 Sep; 11(3):238-50. PubMed ID: 6435249
[No Abstract] [Full Text] [Related]
30. HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
Coleman M; Pasmantier MW; Silver RT
Cancer; 1985 May; 55(10):2342-7. PubMed ID: 3921228
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
Schwartz PE; Lawrence R; Katz M
Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
[TBL] [Abstract][Full Text] [Related]
32. Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens.
Vogl SE; Pagano M; Kaplan BH; Greenwald E; Arseneau J; Bennett B
Cancer; 1983 Jun; 51(11):2024-30. PubMed ID: 6404547
[TBL] [Abstract][Full Text] [Related]
33. Cis-diamminedichloroplatinum (II): second line induction chemotherapy in advanced ovarian adenocarcinoma.
Piver MS; Barlow JJ; Lele SB; Malfetano JH; McPhee ME
J Surg Oncol; 1983 Dec; 24(4):329-31. PubMed ID: 6418977
[TBL] [Abstract][Full Text] [Related]
34. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
Bruckner HW; Cohen CJ; Feuer E; Holland JF
Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
[TBL] [Abstract][Full Text] [Related]
35. A review of 28 years of treating advanced ovarian cancer.
Krommer CF; Szalai JP
Anticancer Res; 1993; 13(3):817-25. PubMed ID: 8317918
[TBL] [Abstract][Full Text] [Related]
36. Intraperitoneal chemotherapy for advanced ovarian cancer.
Lucas WE; Markman M; Howell SB
Am J Obstet Gynecol; 1985 Jun; 152(4):474-8. PubMed ID: 3925784
[TBL] [Abstract][Full Text] [Related]
37. [Chemotherapy of epithelial ovarian cancer: CHexUP versus thio-tepa].
Wu BZ
Zhonghua Fu Chan Ke Za Zhi; 1987 Jan; 22(1):5-8, 61. PubMed ID: 3109851
[No Abstract] [Full Text] [Related]
38. Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer.
Yokoyama Y; Futagami M; Fukushi Y; Sakamoto T; Higuchi T; Fujii S; Sato S; Takami H; Saito Y
Arch Gynecol Obstet; 2000 Apr; 263(4):206-7. PubMed ID: 10834334
[TBL] [Abstract][Full Text] [Related]
39. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
[TBL] [Abstract][Full Text] [Related]
40. CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapy.
Schwartz PE; Keating G; Kohorn EI; Chambers JT
Gynecol Oncol; 1986 Nov; 25(3):340-6. PubMed ID: 3096820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
